Work

1083 Induction of anti-cancer immunity by immunopeptidome-guided personalized peptide vaccines in advanced solid tumor patients

Year: 2026
Type: conference-abstract
Abstract: Background After decades of limited clinical success, therapeutic cancer vaccines have regained attention within the area of immunotherapy. This low-side-effect treatment aims to induce T cell responses against human leukocyte antigen (HLA)-presented peptides displayed on tumor cells. It has the potential to establish long-term immunological memory and promote durable disease control. To advance this approach, we developed a multi-omics-based peptide vaccine platform enabling rapid, personalized identification of mutated and non-mutated naturally presented tumor antigens.Methods The workflow integrates whole-exome or tumor panel sequencing with mass spectrometry-based immunopeptidome profiling of individual patient tumor tissue. For personalized vaccine peptide selection, multi-omics data are compared with our comprehensive immunopeptidome database of malignant (n = 1,335) and benign tissues (n = 569), enabling identification of frequent tumor-associated peptides and mutation-derived neoepitopes. This workflow is applicable across tumor entities and mutational burdens and relies solely on analyses of single small biopsy samples. Based on this approach, personalized peptide vaccines adjuvanted with the TLR1/2 agonist XS15 emulsified in Montanide ISA51 VG were generated and administered within a compassionate use program ( NCT05014607) to 39 patients with advanced metastatic solid tumors across 17 tumor entities.Results The patient cohort included heavily pretreated patients with poor-prognosis malignancies, including amongst others metastatic sarcoma, colorectal carcinoma, and cholangiocarcinoma. Vaccine-induced T cell responses were observed in 100% of patients after two doses of the personalized vaccine. Adverse events were mild-to-moderate, primarily local, and without systemic immune reactions. Low-frequency pre-existing T cell responses before vaccination were identified in 44% of patients, recognizing an average of 12.5% of vaccine peptides, supporting the pathophysiological relevance of the selected peptides in cancer immune surveillance. Overall, 346 tumor-derived peptides were included in the personalized peptide vaccines, of which 67% elicited multifunctional CD4 + and/or CD8+ T cell responses characterized by TNF, IFN-γ, and/or IL-2 production, and CD107a expression. Vaccine-induced T cell responses persisted for up to 6.5 years. Median overall survival was 27 months, and 49% of patients survived for more than 2 years after vaccination, substantially surpassing statistically expected life expectancy for such advanced-stage diseases. Of note, prolonged patient survival was associated with strong immune responses induced by the vaccine.Conclusions Integrating immunopeptidome-based profiling of tumor antigen presentation with characterization of vaccine-induced T cell phenotype and functionality offers important insights for refining peptide-based vaccines and advancing clinical translation. Our findings demonstrate the feasibility of this personalized peptide vaccine strategy and provide strong evidence for its immunological activity and clinical promise.Ethics Approval The treatment of the patient was performed within a compassionate use program (expanded access) for personalized peptide vaccination under the project: clinicaltrials.gov NCT05014607. The local Ethics Committee (406/2019BO2) and the regulatory authority (Regierungspräsidium Tübingen) approved the project which was conducted under the German Drug Law §13 paragraph 2b.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225162038
Cites:
Cited by:
Related to: 10